CELYAD ONCOLOGY SA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.34 EUR | +6.25% |
|
-2.86% | -12.82% |
| Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
| Sales 2022 | - | Sales 2023 | 102K 108K | Capitalization | 16.16M 17.18M |
|---|---|---|---|---|---|
| Net income 2022 | -40M -42.54M | Net income 2023 | -8M -8.51M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 12.96M | Net cash position 2023 | 5.95M 6.32M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| 1 day | +6.25% | ||
| 1 week | -2.86% | ||
| Current month | -3.13% | ||
| 1 month | -5.56% | ||
| 3 months | -5.56% | ||
| 6 months | -55.15% | ||
| Current year | -12.82% |
1 week
0.31
0.36
1 month
0.300.38
Current year
0.300.47
1 year
0.301.28
3 years
0.306.02
5 years
0.3019.50
10 years
0.3070.95
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 0.34 | +6.25% | 10,091 |
| 24-04-12 | 0.32 | -8.05% | 33,574 |
| 24-04-11 | 0.348 | +4.50% | 20,166 |
| 24-04-10 | 0.333 | -6.98% | 38,141 |
| 24-04-09 | 0.358 | +2.29% | 11,880 |
Real-time Euronext Bruxelles, April 15, 2024 at 11:36 am EDT
More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.82% | 14.1M | |
| +0.62% | 42.63B | |
| +50.98% | 42.32B | |
| +4.34% | 40.26B | |
| -11.36% | 27.27B | |
| +6.84% | 25.24B | |
| -22.18% | 18.78B | |
| +0.56% | 12.39B | |
| +28.90% | 12.24B | |
| +7.64% | 10.95B |
- Stock Market
- Equities
- CYAD Stock
